Treatment of age-related cognitive dysfunction; pharmacological and clinical evaluation: Edited by G. Racagni and J. Mendlewicz. 154 pp. 1992. S. Karger, Basel, S.Fr 154 DM166; $111.25

Abstract

Failure of integrative mechanisms in the ageing brain, K. Fuxe et al cholinergic mechanism and trophic factors, M. Knipper and H.I. Yamamura age-related quantitative and qualitative receptor changes and pharmacological reactivity, W.E. Muller amino acid receptors and long-term potentiation - targets for the development of cognitive enhancers, G.L. Collingridge et al preclinical evaluation of potential cognition enhancers, R.D. Porsolt et al morphological brain changes induced by alcohol and ageing - effects of piracetam during withdrawal following long-term alcohol consumption, F. Brandao et al age-associated memory impairment, K.C. Raffaele et al Alzheimer's disease is caused by mismetabolism of the beta-amyloid precursor protein, J. Hardy definition and classification of age-related cognitive dysfunction, L. Amaducci et al assessment of clinical efficacy of cognitive enhancers, T.H. Crook developing pharmacological treatment for age associated cognitive impairments - a regulatory perspective, P. Leber impact of European regulations in drug development, F. Sauer reappraisal of current therapy in the treatment of age-related cognitive disorders, C.G. Gottfries interaction between cognitive and pharmacological treatment in age-related cognitive impairment, W. Deberdt the next decade in drug treatment of cognitive disorders, C.E. Giurgea panel discussion - regulatory issues in the development of drugs for the treatment of cognitive dysfunctions, L. Amaducci et al.